Venlafaxine Hcl Er

MAOI with properties that increase risk of serotonin syndrome when used with venlafaxine. Contraindicated.

Concomitant use contraindicated. Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine.

MAOI with properties that increase risk of serotonin syndrome when used with venlafaxine. Contraindicated.

Concomitant use increases risk of serotonin syndrome. Contraindicated in patients taking MAOIs.

Concomitant use of venlafaxine with tryptophan supplements are not recommended due to risk of serotonin syndrome.

Potential for serotonin syndrome when used with serotonergic drugs. Careful patient observation advised.

Potential for serotonin syndrome when used with serotonergic drugs. Careful patient observation advised.

Potential for serotonin syndrome when used with serotonergic drugs. Careful patient observation advised.

Potential for serotonin syndrome when used with serotonergic drugs. Careful patient observation advised.

CNS-active substance with unsystematically evaluated risk when combined with venlafaxine. Caution advised.

Concomitant use may potentiate bleeding risk. Closely monitor for bleeding when initiating or discontinuing venlafaxine.

May potentiate risk of upper gastrointestinal bleeding when used with venlafaxine due to serotonin reuptake inhibition affecting platelet hemostasis.

Inhibits first-pass metabolism of venlafaxine, increasing AUC and Cmax by about 60%. Caution advised in patients with pre-existing hypertension, elderly patients, and those with hepatic dysfunction.

Risk of concomitant use with CNS-active drugs has not been systematically evaluated. Caution advised when used together.

Venlafaxine increases haloperidol AUC and Cmax. Caution recommended with co-administration.

Increases venlafaxine and O-desmethylvenlafaxine AUC and Cmax. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4.

Increase Cmax and AUC of venlafaxine and ODV, which may increase toxicity risk. Consider reducing venlafaxine dose.

( 7.7 ) Metoprolol: Possibly reduced blood pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. Metoprolol - Concomitant administration of venlafaxine (50 mg every 8 hours for 5 days) and metoprolol (100 mg every 24 hours for 5 days) to 18 healthy male subjects in a pharmacokinetic interaction study for both drugs resulted in an increase of plasma concentrations of metoprolol by approximately 30-40% without altering the plasma concentrations of its active metabolite, α‑hydroxymetoprolol.

Concomitant use may potentiate bleeding risk. Closely monitor for bleeding when initiating or discontinuing venlafaxine.

Safety and efficacy of coadministration not established; concurrent use not recommended.

Risk of serotonin syndrome due to additive serotonergic effects; careful observation required during treatment initiation and dose increases.

Altered anticoagulant effects and increased bleeding risk reported; patients should be carefully monitored when venlafaxine is initiated or discontinued.

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.

Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam.

7.3 Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. Venlafaxine also did not have any effect on the pharmacokinetics of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.

Indinavir - In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir C max . Indinavir did not affect the pharmacokinetics of venlafaxine and ODV.

In vivo , venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide.